On August 26, PHARMARON fell 3.02% in regular trading, trading at 31.6 HKD/share, with turnover of HKD 107 million. The decline came amid broad weakness across the CXO sector, with peers WUXI APPTEC down 2.15% and WUXI XDC down 2.87%, dragging individual names lower through sector linkage.

On the news front, the company's A-share listing experienced a significant 6.50% single-day drop on August 24, reflecting notable short-term selling pressure. While PHARMARON recently announced plans to repurchase up to 10% of its issued H-shares (approximately 35.81 million shares) and JPMorgan increased its stake by 4.04 million shares on August 20 at HKD 34.04 per share, market sentiment remained cautious. The mid-year report revealed operating cash flow declined 23% year-over-year despite revenue growth of 17.9% to RMB 7.595 billion. Additionally, more than 10 institutions have disclosed reduced positions, intensifying near-term selling pressure and offsetting the positive signals from the buyback authorization and international bank upgrades.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)